Health Canada

Iovance Biotherapeutics reduced its workforce by 19% in Q3 2025 and targets $100 million in annual savings to extend cash runway to late 2026.

Iovance Biotherapeutics achieved $60.0 million in total product revenue for Q2 2025, representing a 93% year-over-year increase driven by strong Amtagvi adoption.

Rapid Dose Therapeutics has submitted a product application to Health Canada for approval of its QuickStrip Nicotine products in four dose strengths (1-4 mg), marking a significant regulatory milestone for the innovative oral nicotine delivery system.

Health Canada has granted approval for XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use in treating uveitic macular edema, expanding the drug's global reach.

Nanochon has received Health Canada approval for a first-in-human clinical trial of its 3D printed Chondrograft implant to treat articular cartilage defects in the knee.

Health Canada has extended approval of Evkeeza (evinacumab) to treat children as young as 6 months old with homozygous familial hypercholesterolemia (HoFH), a devastating inherited cholesterol disorder.

Solid Biosciences has received FDA IND and Health Canada CTA approval for SGT-501, a novel gene therapy designed to treat catecholaminergic polymorphic ventricular tachycardia (CPVT), a rare genetic heart condition that can cause sudden death.

MedMira has launched a clinical trial to evaluate its Multiplo TP/HIV rapid test for self-testing use in Canada, with first participants enrolled at sites in Victoria and Toronto.

AbCellera Biologics has received Health Canada authorization to begin Phase 1 trials for ABCL635, a first-in-class NK3R antagonist targeting menopause-related hot flashes, and ABCL575, an OX40L-targeting antibody for atopic dermatitis, both scheduled to start in Q3 2025.

Quebec implemented public reimbursement of Pluvicto (lutetium-177 vipivotide tetraxetan) as of July 2, 2025, for eligible patients with PSMA-positive metastatic castration-resistant prostate cancer.